Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Regeneron pharmaceuticals, inc. save search
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
Regeneron Provides Update on Biologics License Application for Odronextamab
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.37%
H: 1.15%
C: 0.74%
license update application
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Published: 2024-03-13 (Crawled : 02:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: -1.46%
million cancer research
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Society for Science Fuels Innovation with $110K in Educator Grants, Transforming Classrooms for Student STEM Research
Published: 2024-02-21 (Crawled : 14:30) - prnewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.54%
H: 0.63%
C: 0.09%
innovation research
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Published: 2024-02-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.54%
H: 0.63%
C: 0.09%
fda review treatment
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.14%
H: 0.32%
C: -0.57%
dupixent first japan urticaria world
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.14%
H: 0.32%
C: -0.57%
dupixent first japan urticaria world
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2024-02-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
treatment ema
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
Published: 2024-01-24 (Crawled : 17:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: -0.92%
million awards
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.83%
H: 1.57%
C: -2.61%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.02%
H: 0.77%
C: -0.61%
evkeeza positive hypercholesterolemia
Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.66%
H: 0.0%
C: -0.12%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -2.93%
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.31%
H: 0.39%
C: -0.44%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.18%
H: 0.5%
C: -0.46%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.78%
H: 5.15%
C: 2.81%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.52%
H: 0.58%
C: 0.05%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.34%
H: 1.02%
C: 0.59%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.57%
H: 1.36%
C: 1.04%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.06%
H: 0.18%
C: -1.06%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.24%
H: 2.03%
C: 1.49%
patent report global market
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Published: 2023-12-18 (Crawled : 13:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.07%
H: 1.61%
C: -0.61%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.62%
H: 0.48%
C: -0.34%
evkeeza children hypercholesterolemia
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
Published: 2023-12-11 (Crawled : 12:30) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.2%
H: 1.35%
C: 1.19%
index jones year world
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.